No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
NVS240719C105000
- 7.31
- +0.71+10.76%
15min DelayClose Jul 12 15:59 ET
7.40High7.25Low
7.40Open6.60Pre Close5 Volume1.86K Open Interest105.00Strike Price3.65KTurnover71.37%IV0.55%PremiumJul 19, 2024Expiry Date6.70Intrinsic Value100Multiplier5DDays to Expiry0.61Extrinsic Value100Contract SizeAmericanOptions Type0.7795Delta0.0308Gamma13.88Leverage Ratio-0.2861Theta0.0115Rho10.82Eff Leverage0.0399Vega
Intraday
- 5D
- Daily
News
MorphoSys Declares Voluntary Delisting From Nasdaq
Express News | Novartis AG : Morgan Stanley Raises Target Price to $114 From $110
Top Gap Ups and Downs on Thursday: IBKR, DAL, VOD and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.
Novartis On Pace for Record High Close -- Data Talk
Novartis AG Sponsored ADR (NVS) is currently at $108.97, up $0.74 or 0.68% --Would be new all-time high (Based on available data back to Dec. 24, 1996) --Would be the first record close since Jan. 22,
Top Gap Ups and Downs on Tuesday: BABA, TTE, MUFG and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.
Citi Research's AI Hedge Stocks - Part II
Comments
Keep an eye on these recently announced M&As: 👀
$Merck & Co(MRK.US$ to acquire EyeBio
$Biogen(BIIB.US$ to acquire HI-Bio™
$Johnson & Johnson(JNJ.US$ to acquire Proteologix
OnKure, Inc. merger with $Reneo Pharmaceuticals(RPHM.US$
$Novartis AG(NVS.US$ to acquire Mariana Oncology
What companies will be next? 🤔
$Merck & Co(MRK.US$ to acquire EyeBio
$Biogen(BIIB.US$ to acquire HI-Bio™
$Johnson & Johnson(JNJ.US$ to acquire Proteologix
OnKure, Inc. merger with $Reneo Pharmaceuticals(RPHM.US$
$Novartis AG(NVS.US$ to acquire Mariana Oncology
What companies will be next? 🤔
4
$Esperion Therapeutics(ESPR.US$ Multiple sources indicate that Esperion's advancements and commercial success with its cholesterol-lowering drugs, NEXLIZET and NEXLETOL, have positioned it as defininte acquistion target for larger pharmaceutical companies. Esperion's drugs NEXLIZET and NEXLETOL now have primary prevention labels, NEXLIZET will soon become the drug of choice over a PCSK9 inhibitor says Texas based HeartPlace leading Cardio...
12
Stories you might have missed ![]()
Singapore’s private home sales down nearly half in February; 149 condos sold amid holiday lull
DEVELOPERS in Singapore sold 149 private homes in February, 47 per cent fewer than the 281 units moved in January, data released on Friday (Mar 15) by the Urban Redevelopment Authority showed.
Novartis invests US$256 million to expand Singapore plant
SWISS biopharma giant Novartis has invested US$256 million to expand its biopharm...
Singapore’s private home sales down nearly half in February; 149 condos sold amid holiday lull
DEVELOPERS in Singapore sold 149 private homes in February, 47 per cent fewer than the 281 units moved in January, data released on Friday (Mar 15) by the Urban Redevelopment Authority showed.
Novartis invests US$256 million to expand Singapore plant
SWISS biopharma giant Novartis has invested US$256 million to expand its biopharm...
7
Google's disappointing ad sales growth and AMD's lower revenue guidance have hurt investor sentiment, causing their shares to drop. Byron Allen's offer to acquire Paramount Global is seen as beneficial for shareholders, boosting its share price. Novartis AG's lower Q4 earnings and adjusted mid-term guidance have led to a share price decline.
JPMorgan analysts predict a strong uptake for Novartis's various treatments to boost the company's top line, with cost savings from restructuring aiding the bottom line. Morgan Stanley analysts note Novartis's need for external innovation to meet long-term growth ambitions.
Read more